Literature DB >> 23397358

Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis.

Lei Zhang1, Xiaojun Wu, Tao Xu, Chun Luo, Jun Qian, Yicheng Lu.   

Abstract

OBJECT: The aim of this study was to answer whether overall survival and progression-free survival are increased in patients with anaplastic glioma who are treated with radiotherapy plus chemotherapy as compared with those who treated with radiotherapy alone.
METHODS: Searches of the MEDLINE (PubMed), Embase and Cochrane Library from January 2001 to May 2012 for relevant trials were undertaken. Selected studies based on the following criteria: First, only randomized clinical trial of adjuvant radiotherapy plus chemotherapy versus radiotherapy alone was permitted. Second, overall survival and/or progression-free survival was compared with patients in the studies. Third, cases were medically confirmed of anaplastic glioma.
RESULTS: 4 randomized clinical trials were found eligible for this article (involving a total of 963 patients). The meta-analysis showed a significant increase in overall survival in patients treated with radiotherapy plus chemotherapy (HR = 0.84, 95 % CI 0.72-0.98, P = 0.031).
CONCLUSIONS: Results of our meta-analysis indicated that adjuvant chemotherapy played a beneficial role in the treatment for anaplastic gliomas. But the role of adjuvant chemotherapy in the treatment for anaplastic astrocytoma or anaplastic oligodendroglioma/anaplastic oligoastrocytoma still needs further large randomized trials to demonstrate.

Entities:  

Mesh:

Year:  2013        PMID: 23397358     DOI: 10.1007/s00432-013-1387-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).

Authors:  Silvia Scoccianti; Stefano Maria Magrini; Umberto Ricardi; Beatrice Detti; Marco Krengli; Salvatore Parisi; Filippo Bertoni; Guido Sotti; Samantha Cipressi; Vincenzo Tombolini; Stefano Dall'oglio; Marco Lioce; Calogero Saieva; Michela Buglione; Cristina Mantovani; Giovanni Rubino; Paolo Muto; Vincenzo Fusco; Laura Fariselli; Costantino de Renzis; Laura Masini; Riccardo Santoni; Luigi Pirtoli; Giampaolo Biti
Journal:  Neuro Oncol       Date:  2012-04-25       Impact factor: 12.300

3.  Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.

Authors:  Meihua Wang; Gregory Cairncross; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

4.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Authors:  Helen Athanassiou; Maria Synodinou; Evagelos Maragoudakis; Mihalis Paraskevaidis; Cosmas Verigos; Despina Misailidou; Dosia Antonadou; George Saris; Konstantinos Beroukas; Pantelis Karageorgis
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Authors:  Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

Review 8.  Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis.

Authors:  Abraham Tsitlakidis; Nicolas Foroglou; Christos A Venetis; Ioannis Patsalas; Athanasios Hatzisotiriou; Panagiotis Selviaridis
Journal:  J Neurosurg       Date:  2010-05       Impact factor: 5.115

9.  Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).

Authors:  Jerzy Hildebrand; Thierry Gorlia; Johan M Kros; Dénes Afra; Marc Frenay; Antonio Omuro; Roger Stupp; Denis Lacombe; Anouk Allgeier; Martin J van den Bent
Journal:  Eur J Cancer       Date:  2008-01-14       Impact factor: 9.162

10.  Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.

Authors:  Chul-Kee Park; Se-Hoon Lee; Jung Ho Han; Chae-Yong Kim; Dong-Wan Kim; Sun Ha Paek; Dong Gyu Kim; Dae Seog Heo; Il Han Kim; Hee-Won Jung
Journal:  BMC Cancer       Date:  2009-12-18       Impact factor: 4.430

View more
  3 in total

1.  MiR-199a Inhibits Tumor Growth and Attenuates Chemoresistance by Targeting K-RAS via AKT and ERK Signalings.

Authors:  Wei Li; Lin Wang; Xiang-Bo Ji; Li-Hong Wang; Xin Ge; Wei-Tao Liu; Ling Chen; Zhong Zheng; Zhu-Mei Shi; Ling-Zhi Liu; Marie C Lin; Jie-Yu Chen; Bing-Hua Jiang
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

2.  microRNA-149 targets caspase-2 in glioma progression.

Authors:  Xiaokun Shen; Jie Li; Wenfeng Liao; Jiwen Wang; Huanjun Chen; Yanli Yao; Houbao Liu; Kan Ding
Journal:  Oncotarget       Date:  2016-05-03

3.  Long Noncoding RNA LINC00467 Promotes Glioma Progression through Inhibiting P53 Expression via Binding to DNMT1.

Authors:  Yin Zhang; Xuefeng Jiang; Zhisheng Wu; Daling Hu; Junli Jia; Jinfeng Guo; Tian Tang; Jialin Yao; Hongyi Liu; Huamin Tang
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.